Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study

Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods...

Full description

Saved in:
Bibliographic Details
Published inJournal of the International AIDS Society Vol. 27; no. 2; pp. e26200 - n/a
Main Authors Rosen, Joseph Gregory, Ssekubugu, Robert, Chang, Larry W., Ssempijja, Victor, Galiwango, Ronald M., Ssekasanvu, Joseph, Ndyanabo, Anthony, Kisakye, Alice, Nakigozi, Gertrude, Rucinski, Katherine B., Patel, Eshan U., Kennedy, Caitlin E., Nalugoda, Fred, Kigozi, Godfrey, Ratmann, Oliver, Nelson, Lisa J., Mills, Lisa A., Kabatesi, Donna, Tobian, Aaron A. R., Quinn, Thomas C., Kagaayi, Joseph, Reynolds, Steven J., Grabowski, Mary Kathryn
Format Journal Article
LanguageEnglish
Published Switzerland John Wiley & Sons, Inc 01.02.2024
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
AbstractList Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
IntroductionPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.MethodsIn 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200–999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.ResultsOverall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).ConclusionsFollowing universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up. In 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Overall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%). Following universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
Introduction: Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods: In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results: Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions: Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.INTRODUCTIONPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale-up.In 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.METHODSIn 2015-2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/ml) or high-level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit-pairs; ∼18-month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow-up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations.Overall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).RESULTSOverall, 3080 participants contributed 4604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow-up, 91.3% of which was high-level viraemia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viraemia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viraemia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (vs. 40- to 49-year-olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21-3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10-1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03-1.16). The prevalence of persistent high-level viraemia was highest among males <30 years (32.0%).Following universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.CONCLUSIONSFollowing universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high-level viraemia for ≥12 months and reported higher-risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.
Audience Academic
Author Rosen, Joseph Gregory
Kisakye, Alice
Ndyanabo, Anthony
Patel, Eshan U.
Ssekubugu, Robert
Kigozi, Godfrey
Kennedy, Caitlin E.
Grabowski, Mary Kathryn
Ssekasanvu, Joseph
Reynolds, Steven J.
Chang, Larry W.
Galiwango, Ronald M.
Rucinski, Katherine B.
Nalugoda, Fred
Kagaayi, Joseph
Mills, Lisa A.
Ratmann, Oliver
Kabatesi, Donna
Tobian, Aaron A. R.
Quinn, Thomas C.
Ssempijja, Victor
Nakigozi, Gertrude
Nelson, Lisa J.
Author_xml – sequence: 1
  givenname: Joseph Gregory
  orcidid: 0000-0003-4991-4033
  surname: Rosen
  fullname: Rosen, Joseph Gregory
  email: jrosen72@jhu.edu
  organization: Johns Hopkins Bloomberg School of Public Health
– sequence: 2
  givenname: Robert
  surname: Ssekubugu
  fullname: Ssekubugu, Robert
  organization: Rakai Health Sciences Program
– sequence: 3
  givenname: Larry W.
  surname: Chang
  fullname: Chang, Larry W.
  organization: Johns Hopkins Bloomberg School of Public Health
– sequence: 4
  givenname: Victor
  orcidid: 0000-0003-2609-6525
  surname: Ssempijja
  fullname: Ssempijja, Victor
  organization: Frederick National Laboratory for Cancer Research
– sequence: 5
  givenname: Ronald M.
  surname: Galiwango
  fullname: Galiwango, Ronald M.
  organization: Rakai Health Sciences Program
– sequence: 6
  givenname: Joseph
  surname: Ssekasanvu
  fullname: Ssekasanvu, Joseph
  organization: Rakai Health Sciences Program
– sequence: 7
  givenname: Anthony
  surname: Ndyanabo
  fullname: Ndyanabo, Anthony
  organization: Rakai Health Sciences Program
– sequence: 8
  givenname: Alice
  surname: Kisakye
  fullname: Kisakye, Alice
  organization: Rakai Health Sciences Program
– sequence: 9
  givenname: Gertrude
  surname: Nakigozi
  fullname: Nakigozi, Gertrude
  organization: Rakai Health Sciences Program
– sequence: 10
  givenname: Katherine B.
  orcidid: 0000-0002-9858-5953
  surname: Rucinski
  fullname: Rucinski, Katherine B.
  organization: Johns Hopkins Bloomberg School of Public Health
– sequence: 11
  givenname: Eshan U.
  surname: Patel
  fullname: Patel, Eshan U.
  organization: Johns Hopkins Bloomberg School of Public Health
– sequence: 12
  givenname: Caitlin E.
  orcidid: 0000-0001-6820-063X
  surname: Kennedy
  fullname: Kennedy, Caitlin E.
  organization: Rakai Health Sciences Program
– sequence: 13
  givenname: Fred
  surname: Nalugoda
  fullname: Nalugoda, Fred
  organization: Rakai Health Sciences Program
– sequence: 14
  givenname: Godfrey
  surname: Kigozi
  fullname: Kigozi, Godfrey
  organization: Rakai Health Sciences Program
– sequence: 15
  givenname: Oliver
  surname: Ratmann
  fullname: Ratmann, Oliver
  organization: Imperial College
– sequence: 16
  givenname: Lisa J.
  surname: Nelson
  fullname: Nelson, Lisa J.
  organization: Centers for Disease Control and Prevention
– sequence: 17
  givenname: Lisa A.
  surname: Mills
  fullname: Mills, Lisa A.
  organization: Centers for Disease Control and Prevention
– sequence: 18
  givenname: Donna
  surname: Kabatesi
  fullname: Kabatesi, Donna
  organization: Centers for Disease Control and Prevention
– sequence: 19
  givenname: Aaron A. R.
  surname: Tobian
  fullname: Tobian, Aaron A. R.
  organization: Johns Hopkins School of Medicine
– sequence: 20
  givenname: Thomas C.
  surname: Quinn
  fullname: Quinn, Thomas C.
  organization: National Institutes of Health
– sequence: 21
  givenname: Joseph
  surname: Kagaayi
  fullname: Kagaayi, Joseph
  organization: Rakai Health Sciences Program
– sequence: 22
  givenname: Steven J.
  surname: Reynolds
  fullname: Reynolds, Steven J.
  organization: National Institutes of Health
– sequence: 23
  givenname: Mary Kathryn
  orcidid: 0000-0002-4451-3436
  surname: Grabowski
  fullname: Grabowski, Mary Kathryn
  organization: Johns Hopkins School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38332519$$D View this record in MEDLINE/PubMed
BookMark eNp9kstuEzEUhkeoiF5gwwMgS0gIIaXYnvFcuosqoEGV2KRsrRP7TOLIsQd7plV2PAIPxZPwJDiTUlpUIS9sHX__b5_LcXbgvMMse8noKaOUv18b4Ke85JQ-yY5YJeoJLwU_uHc-zI5jXFNa8rponmWHeZ3nXLDmKPs5x03nA1iitw42RkUCThMdzDWGSHxL9BBgYZFczL6Sa7MjrQdN4tB1AWM03o2KLuEm9uh6sjLL1a_vP8aw9TfpaPEa7ajGjYGdpXFLcuXGR5LjHGM_4vOA0JOowGKSDR0xjlwt0w2cESCd7wYLfXoyXS4gYvpGP-jt8-xpCzbii9v9JLv6-GF-fjG5_PJpdj69nCghCjrRoFsQwEslWgU5S4WhikJVFFhUulQt0zpnCijQWrAW60UDXDcNq1ihNUB-ks32vtrDWnbBbCBspQcjx4APSwmhN8qipFSUbYklipYWomSNqFRRVTVWSkOuaPJ6u_fqgv82pPzlxkSF1oJDP0TJG140TVmIOqGv_0HXfgguZZqonNXJn5Z_qWUqnjSu9X0AtTOV06phtGS04omaPEIt0WHqbBqr1qTwA_70ET4tnTqpHhW8uSdYIdh-Fb0ddl2LD8FXt1kNiw3qu3L-mc0EvNsDKvgYA7Z3CKNyN_hyN_hyHPwEsz18k_6z_Q8pP8-mfK_5DYcRB6Y
Cites_doi 10.1080/17441692.2015.1074715
10.1056/NEJMoa1812281
10.1186/s12879-017-2680-6
10.1056/NEJMoa1814556
10.1002/jia2.25517
10.1097/QAI.0000000000002811
10.1016/j.jviromet.2013.04.003
10.1093/aje/kwn164
10.1097/QAD.0000000000002538
10.1097/QAI.0000000000000489
10.7448/IAS.20.1.21590
10.1097/EDE.0000000000000409
10.1086/498515
10.1016/S2352-3018(21)00069-2
10.1155/2013/470245
10.1016/S2352-3018(17)30205-9
10.1097/QAD.0000000000003388
10.1038/s41467-020-14636-y
10.1371/journal.pmed.1001610
10.1111/hiv.13203
10.1136/bmjgh-2021-007312
10.1097/QAD.0000000000001536
10.1016/S2352-3018(19)30402-3
10.1002/jia2.26033
10.1007/s11904-020-00492-4
10.1097/MD.0000000000003985
10.1080/09540121.2019.1595509
10.7448/IAS.19.1.21106
10.1371/journal.pmed.1003042
10.1093/infdis/jir353
10.1016/S2214-109X(22)00413-2
10.1056/NEJMoa1809866
10.15585/mmwr.mm6948a1
10.1002/jia2.25048
10.1111/j.0006-341X.2001.00120.x
10.1002/jia2.26005
10.1016/S2352-3018(19)30190-0
10.1177/019251396017003001
10.1093/infdis/jiab021
10.1097/QAD.0000000000002989
10.1093/cid/ciaa413
10.1016/j.drugalcdep.2021.109005
10.1056/NEJMoa1702150
10.1371/journal.pone.0256865
10.1016/S2352-3018(20)30359-3
10.1016/S0140-6736(23)00877-2
10.1097/QAI.0000000000002508
10.1007/s10461-022-03582-z
10.1016/S2352-3018(16)30034-0
10.1056/NEJMp1710608
10.1016/S2352-3018(19)30407-2
ContentType Journal Article
Copyright 2024 The Authors. published by John Wiley & Sons Ltd on behalf of International AIDS Society.
2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
COPYRIGHT 2024 John Wiley & Sons, Inc.
2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Authors. published by John Wiley & Sons Ltd on behalf of International AIDS Society.
– notice: 2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
– notice: COPYRIGHT 2024 John Wiley & Sons, Inc.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOA
DOI 10.1002/jia2.26200
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE



MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1758-2652
EndPage n/a
ExternalDocumentID oai_doaj_org_article_0056f6e6e5f04561957c4778e7cda3c0
A791061072
38332519
10_1002_jia2_26200
JIA226200
Genre article
Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Uganda
Lake Victoria
Africa
GeographicLocations_xml – name: Uganda
– name: Lake Victoria
– name: Africa
GrantInformation_xml – fundername: National Institute of Allergy and Infectious Diseases
  funderid: U01AI100031; U01AI075115; R01AI110324; R01AI128779; R01AI123002; R01AI143333; R01AI155080; T32AI102623
– fundername: National Institute of Mental Health
  funderid: R01MH105313; F31MH126796; K01MH129226
– fundername: National Cancer Institute
  funderid: 75N91019D00024
– fundername: National Institute on Drug Abuse
  funderid: F31DA054849
– fundername: U.S. President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention
  funderid: NU2GGH00081
– fundername: NIAID NIH HHS
  grantid: R01 AI155080
– fundername: NIMH NIH HHS
  grantid: K01 MH129226
– fundername: NIAID NIH HHS
  grantid: U01 AI075115
– fundername: NIAID NIH HHS
  grantid: R01 AI128779
– fundername: NIMH NIH HHS
  grantid: F31MH126796
– fundername: NIAID NIH HHS
  grantid: T32 AI102623
– fundername: NCI NIH HHS
  grantid: 75N91019D00024
– fundername: NIAID NIH HHS
  grantid: R01 AI143333
– fundername: NIMH NIH HHS
  grantid: K01MH129226
– fundername: NIDA NIH HHS
  grantid: F31DA054849
GroupedDBID ---
0R~
1OC
24P
29L
2VQ
2WC
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAMMB
ABDBF
ABUWG
ACCMX
ACGFO
ACGFS
ACUHS
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADUKV
ADZMN
AEFGJ
AEGXH
AENEX
AEUYN
AFKRA
AGXDD
AHBYD
AHMBA
AIAGR
AIDQK
AIDYY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMKLP
AOIJS
AVUZU
BAWUL
BCNDV
BENPR
BMC
BPHCQ
BVXVI
C6C
CCPQU
DIK
E3Z
EBD
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
IOF
ITC
KQ8
M1P
M48
M~E
N8Y
O5R
O5S
O9-
OK1
OVD
OVEED
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TEORI
TR2
TUS
UKHRP
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
WIN
7X8
PUEGO
ID FETCH-LOGICAL-c5540-dadfa5a26c5fca316520c0a744e47d6cf1dd31ca0a0851fe8b9a2d991714ddaa3
IEDL.DBID M48
ISSN 1758-2652
IngestDate Wed Aug 27 01:04:21 EDT 2025
Fri Jul 11 16:49:17 EDT 2025
Wed Aug 13 08:37:45 EDT 2025
Tue Jun 17 22:09:23 EDT 2025
Fri Jun 13 00:06:11 EDT 2025
Tue Jun 10 21:02:46 EDT 2025
Thu May 22 21:24:07 EDT 2025
Mon Jul 21 06:02:02 EDT 2025
Tue Jul 01 03:55:14 EDT 2025
Sun Jul 06 04:45:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords HIV treatment
HIV viraemia
prospective cohort
sub-Saharan Africa
Treat All
antiretroviral therapy
Language English
License Attribution
2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5540-dadfa5a26c5fca316520c0a744e47d6cf1dd31ca0a0851fe8b9a2d991714ddaa3
Notes These authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2609-6525
0000-0002-4451-3436
0000-0002-9858-5953
0000-0003-4991-4033
0000-0001-6820-063X
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1002/jia2.26200
PMID 38332519
PQID 2931845606
PQPubID 55048
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_0056f6e6e5f04561957c4778e7cda3c0
proquest_miscellaneous_2924996458
proquest_journals_2931845606
gale_infotracmisc_A791061072
gale_infotracgeneralonefile_A791061072
gale_infotracacademiconefile_A791061072
gale_healthsolutions_A791061072
pubmed_primary_38332519
crossref_primary_10_1002_jia2_26200
wiley_primary_10_1002_jia2_26200_JIA226200
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2024
2024-02-00
20240201
2024-02-01
PublicationDateYYYYMMDD 2024-02-01
PublicationDate_xml – month: 02
  year: 2024
  text: February 2024
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Geneva
PublicationTitle Journal of the International AIDS Society
PublicationTitleAlternate J Int AIDS Soc
PublicationYear 2024
Publisher John Wiley & Sons, Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley
References 2021; 8
2017; 20
1996; 17
2019; 6
2016; 19
2021; 88
2021; 223
2019; 31
2020; 85
2023; 37
2021; 228
2020; 17
2022; 23
2023; 402
2022; 25
2016; 95
2022; 26
2020; 34
2020; 11
2008; 168
2021; 72
2017; 377
2018; 21
2019; 381
2011; 204
2015; 68
2021; 35
2020; 7
2017; 31
2021; 16
2006; 42
2018; 5
2016; 3
2022
2013; 2013
2021
2017; 17
2022; 7
2017; 12
2020; 69
2020; 23
2014
2022; 10
2013; 192
2001; 57
2016; 27
2014; 11
e_1_2_12_4_1
e_1_2_12_6_1
e_1_2_12_19_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_38_1
e_1_2_12_20_1
e_1_2_12_41_1
e_1_2_12_22_1
e_1_2_12_43_1
e_1_2_12_24_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_47_1
e_1_2_12_28_1
e_1_2_12_49_1
e_1_2_12_31_1
e_1_2_12_52_1
e_1_2_12_33_1
e_1_2_12_54_1
e_1_2_12_35_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_14_1
e_1_2_12_12_1
e_1_2_12_8_1
e_1_2_12_10_1
Ssempijja V (e_1_2_12_53_1) 2022; 25
e_1_2_12_50_1
e_1_2_12_3_1
e_1_2_12_5_1
e_1_2_12_18_1
e_1_2_12_16_1
e_1_2_12_39_1
e_1_2_12_42_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_40_1
e_1_2_12_27_1
e_1_2_12_29_1
e_1_2_12_30_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_36_1
e_1_2_12_15_1
e_1_2_12_13_1
e_1_2_12_11_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_9_1
37398460 - medRxiv. 2023 Jun 16:2023.06.15.23291445. doi: 10.1101/2023.06.15.23291445.
References_xml – volume: 402
  start-page: 464
  issue: 10400
  year: 2023
  end-page: 471
  article-title: The risk of sexual transmission of HIV in individuals with low‐level HIV viraemia: a systematic review
  publication-title: Lancet
– volume: 5
  start-page: e116
  issue: 3
  year: 2018
  end-page: e125
  article-title: Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open‐label, community cluster randomised trial
  publication-title: Lancet HIV
– volume: 7
  issue: 1
  year: 2022
  article-title: Mitigating the effects of COVID‐19 on HIV treatment and care in Lusaka, Zambia: a before‐after cohort study using mixed effects regression
  publication-title: BMJ Glob Health
– volume: 34
  start-page: 1065
  issue: 7
  year: 2020
  end-page: 1074
  article-title: Clinic‐level and individual‐level factors that influence HIV viral suppression in adolescents and young adults: a national survey in Kenya
  publication-title: AIDS
– volume: 25
  issue: S3
  year: 2022
  article-title: Population trends in HIV service delivery, viral suppression, and incidence before and during the COVID‐19 era in Rakai, Uganda
  publication-title: J Int AIDS Soc
– volume: 23
  issue: S2
  year: 2020
  article-title: Gendered health institutions: examining the organization of health services and men's use of HIV testing in Malawi
  publication-title: J Int AIDS Soc
– volume: 25
  issue: 11
  year: 2022
  article-title: Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID‐19
  publication-title: J Int AIDS Soc
– volume: 17
  start-page: 249
  issue: 3
  year: 2020
  end-page: 258
  article-title: Integrating and interpreting findings from the latest treatment as prevention trials
  publication-title: Curr HIV/AIDS Rep
– year: 2021
– volume: 88
  start-page: 448
  issue: 5
  year: 2021
  end-page: 456
  article-title: Impact of the COVID‐19 pandemic on use of HIV care, antiretroviral therapy adherence, and viral suppression: an observational cohort study from Uganda
  publication-title: J Acquir Immune Defic Syndr
– volume: 21
  issue: 1
  year: 2018
  article-title: Comparative assessment of five trials of universal HIV testing and treatment in sub‐Saharan Africa
  publication-title: J Int AIDS Soc
– volume: 57
  start-page: 120
  issue: 1
  year: 2001
  end-page: 125
  article-title: Akaike's information criterion in generalized estimating equations
  publication-title: Biometrics
– volume: 95
  issue: 28
  year: 2016
  article-title: Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource‐limited settings
  publication-title: Medicine (Baltimore)
– volume: 20
  start-page: 21590
  issue: 1
  year: 2017
  end-page: 21598
  article-title: Human immunodeficiency virus care cascade among sub‐populations in Rakai, Uganda: an observational study
  publication-title: J Int AIDS Soc
– year: 2014
– volume: 6
  start-page: e680
  issue: 10
  year: 2019
  end-page: e687
  article-title: Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study
  publication-title: Lancet HIV
– volume: 16
  issue: 9
  year: 2021
  article-title: Migration in Namibia and its association with HIV acquisition and treatment outcomes
  publication-title: PLoS One
– volume: 11
  issue: 3
  year: 2014
  article-title: The role of viral introductions in sustaining community‐based HIV epidemics in rural Uganda: evidence from spatial clustering, phylogenetics, and egocentric transmission models
  publication-title: PLoS Med
– volume: 7
  start-page: e229
  issue: 4
  year: 2020
  end-page: e237
  article-title: Point‐of‐care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open‐label, non‐inferiority, randomised controlled trial
  publication-title: Lancet HIV
– volume: 42
  start-page: 136
  issue: 1
  year: 2006
  end-page: 144
  article-title: Virological control during the first 6–18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV‐infected patients: a Danish, population‐based, 6‐year follow‐up study
  publication-title: Clin Infect Dis
– volume: 72
  start-page: 2079
  issue: 12
  year: 2021
  end-page: 2086
  article-title: All‐cause mortality and serious non‐AIDS events in adults with low‐level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study
  publication-title: Clin Infect Dis
– year: 2022
– volume: 10
  start-page: e1815
  issue: 12
  year: 2022
  end-page: e1824
  article-title: Low‐level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study
  publication-title: Lancet Glob Health
– volume: 17
  issue: 3
  year: 2020
  article-title: Mapping and characterising areas with high levels of HIV transmission in sub‐Saharan Africa: a geospatial analysis of national survey data
  publication-title: PLoS Med
– volume: 35
  start-page: 1835
  issue: 11
  year: 2021
  end-page: 1843
  article-title: Household wealth and HIV incidence over time, rural Uganda, 1994–2018
  publication-title: AIDS
– volume: 12
  start-page: 1033
  issue: 8
  year: 2017
  end-page: 1050
  article-title: Mobility among youth in Rakai, Uganda: trends, characteristics, and associations with behavioural risk factors for HIV
  publication-title: Glob Public Health
– volume: 223
  start-page: 1150
  issue: 7
  year: 2021
  end-page: 1160
  article-title: Prevalence and predictors of persistent human immunodeficiency virus viremia and viral rebound after universal test and treat: a population‐based study
  publication-title: J Infect Dis
– volume: 377
  start-page: 2154
  issue: 22
  year: 2017
  end-page: 2166
  article-title: Combination HIV prevention and HIV incidence in Uganda
  publication-title: N Engl J Med
– volume: 204
  start-page: 515
  issue: 4
  year: 2011
  end-page: 520
  article-title: Antiretroviral drug resistance in HIV‐1–infected patients experiencing persistent low‐level viremia during first‐line therapy
  publication-title: J Infect Dis
– volume: 192
  start-page: 25
  issue: 1–2
  year: 2013
  end-page: 27
  article-title: Evaluation of current rapid HIV test algorithms in Rakai, Uganda
  publication-title: J Virol Methods
– volume: 26
  start-page: 2387
  issue: 7
  year: 2022
  end-page: 2396
  article-title: Cyclical engagement in HIV care: a qualitative study of clinic transfers to re‐enter HIV care in Cape Town, South Africa
  publication-title: AIDS Behav
– volume: 23
  start-page: 474
  issue: 5
  year: 2022
  end-page: 484
  article-title: Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first‐line HIV treatment in Uganda and South Africa
  publication-title: HIV Med
– volume: 377
  start-page: 1605
  issue: 17
  year: 2017
  end-page: 1607
  article-title: HIV drug resistance — an emerging threat to epidemic control
  publication-title: N Engl J Med
– volume: 7
  start-page: e209
  issue: 3
  year: 2020
  end-page: e214
  article-title: HIV transmission and source‐sink dynamics in sub‐Saharan Africa
  publication-title: Lancet HIV
– volume: 17
  start-page: 582
  issue: 1
  year: 2017
  article-title: Rates of switching to second‐line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV‐infected adults with virologic failure in Rakai, Uganda
  publication-title: BMC Infect Dis
– volume: 85
  start-page: 571
  issue: 5
  year: 2020
  end-page: 578
  article-title: Improved viral suppression with streamlined care in the SEARCH study
  publication-title: J Acquir Immune Defic Syndr
– volume: 31
  start-page: 1435
  issue: 11
  year: 2019
  end-page: 1446
  article-title: A scoping review on the role of masculine norms in men's engagement in the HIV care continuum in sub‐Saharan Africa
  publication-title: AIDS Care
– volume: 381
  start-page: 207
  issue: 3
  year: 2019
  end-page: 218
  article-title: Effect of universal testing and treatment on HIV incidence — HPTN 071 (PopART)
  publication-title: N Engl J Med
– volume: 17
  start-page: 283
  issue: 3
  year: 1996
  end-page: 316
  article-title: The revised Conflict Tactics Scales (CTS2): development and preliminary psychometric data
  publication-title: J Fam Issues
– volume: 168
  start-page: 656
  issue: 6
  year: 2008
  end-page: 664
  article-title: Constructing inverse probability weights for marginal structural models
  publication-title: Am J Epidemiol
– volume: 68
  start-page: 413
  issue: 4
  year: 2015
  end-page: 419
  article-title: Impact of age on retention in care and viral suppression
  publication-title: J Acquir Immune Defic Syndr
– volume: 31
  start-page: 1637
  issue: 11
  year: 2017
  end-page: 1639
  article-title: HIV drug resistance in Africa: an emerging problem that deserves urgent attention
  publication-title: AIDS
– volume: 8
  start-page: e429
  issue: 7
  year: 2021
  end-page: e439
  article-title: Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population‐based cohort studies
  publication-title: Lancet HIV
– volume: 19
  issue: 1
  year: 2016
  article-title: Marked sex differences in all‐cause mortality on antiretroviral therapy in low‐ and middle‐income countries: a systematic review and meta‐analysis
  publication-title: J Int AIDS Soc
– volume: 11
  start-page: 976
  issue: 1
  year: 2020
  article-title: Migration, hotspots, and dispersal of HIV infection in Rakai, Uganda
  publication-title: Nat Commun
– volume: 69
  start-page: 1801
  issue: 48
  year: 2020
  end-page: 1806
  article-title: Sex differences in HIV testing ‐ 20 PEPFAR‐supported sub‐Saharan African countries, 2019
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 2013
  year: 2013
  article-title: A qualitative study of barriers to enrollment into free HIV care: perspectives of never‐in‐care HIV‐positive patients and providers in Rakai, Uganda
  publication-title: Biomed Res Int
– volume: 3
  start-page: e388
  issue: 8
  year: 2016
  end-page: e396
  article-title: Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study
  publication-title: Lancet HIV
– volume: 27
  start-page: 91
  issue: 1
  year: 2016
  end-page: 97
  article-title: Selection bias due to loss to follow up in cohort studies
  publication-title: Epidemiology
– volume: 381
  start-page: 219
  issue: 3
  year: 2019
  end-page: 229
  article-title: HIV testing and treatment with the use of a community health approach in rural Africa
  publication-title: N Engl J Med
– volume: 381
  start-page: 207
  issue: 3
  year: 2019
  end-page: 218
  article-title: Impact of a universal testing and treatment intervention on HIV incidence in Zambia and South Africa: results of the HPTN 071 (PopART) community‐randomized trial
  publication-title: N Engl J Med
– volume: 37
  start-page: 113
  issue: 1
  year: 2023
  article-title: Male partner age, viral load, and HIV infection in adolescent girls and young women: evidence from eight sub‐Saharan African countries
  publication-title: AIDS
– volume: 8
  start-page: e158
  issue: 3
  year: 2021
  end-page: e165
  article-title: The impact of the COVID‐19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis
  publication-title: Lancet HIV
– volume: 381
  start-page: 230
  issue: 3
  year: 2019
  end-page: 242
  article-title: Universal testing, expanded treatment, and incidence of HIV infection in Botswana
  publication-title: N Engl J Med
– volume: 228
  year: 2021
  article-title: Alcohol use and alcohol‐related consequences are associated with not being virally suppressed among persons living with HIV in the Rakai region of Uganda
  publication-title: Drug Alcohol Depend
– volume: 25
  issue: 4
  year: 2022
  article-title: Progress towards the UNAIDS 90‐90‐90 targets among persons aged 50 and older living with HIV in 13 African countries
  publication-title: J Int AIDS Soc
– ident: e_1_2_12_21_1
  doi: 10.1080/17441692.2015.1074715
– ident: e_1_2_12_3_1
  doi: 10.1056/NEJMoa1812281
– ident: e_1_2_12_37_1
  doi: 10.1186/s12879-017-2680-6
– ident: e_1_2_12_9_1
  doi: 10.1056/NEJMoa1814556
– ident: e_1_2_12_41_1
  doi: 10.1002/jia2.25517
– ident: e_1_2_12_50_1
  doi: 10.1097/QAI.0000000000002811
– ident: e_1_2_12_5_1
  doi: 10.1056/NEJMoa1814556
– ident: e_1_2_12_22_1
  doi: 10.1016/j.jviromet.2013.04.003
– ident: e_1_2_12_54_1
  doi: 10.1093/aje/kwn164
– ident: e_1_2_12_43_1
  doi: 10.1097/QAD.0000000000002538
– ident: e_1_2_12_56_1
  doi: 10.1097/QAI.0000000000000489
– ident: e_1_2_12_44_1
  doi: 10.7448/IAS.20.1.21590
– ident: e_1_2_12_55_1
  doi: 10.1097/EDE.0000000000000409
– ident: e_1_2_12_12_1
  doi: 10.1086/498515
– ident: e_1_2_12_35_1
  doi: 10.1016/S2352-3018(21)00069-2
– ident: e_1_2_12_47_1
  doi: 10.1155/2013/470245
– ident: e_1_2_12_2_1
  doi: 10.1016/S2352-3018(17)30205-9
– ident: e_1_2_12_46_1
  doi: 10.1097/QAD.0000000000003388
– ident: e_1_2_12_17_1
  doi: 10.1038/s41467-020-14636-y
– ident: e_1_2_12_32_1
  doi: 10.1371/journal.pmed.1001610
– ident: e_1_2_12_38_1
  doi: 10.1111/hiv.13203
– ident: e_1_2_12_52_1
  doi: 10.1136/bmjgh-2021-007312
– ident: e_1_2_12_36_1
  doi: 10.1097/QAD.0000000000001536
– ident: e_1_2_12_39_1
  doi: 10.1016/S2352-3018(19)30402-3
– ident: e_1_2_12_49_1
  doi: 10.1002/jia2.26033
– ident: e_1_2_12_11_1
  doi: 10.1007/s11904-020-00492-4
– ident: e_1_2_12_19_1
  doi: 10.1097/MD.0000000000003985
– ident: e_1_2_12_40_1
  doi: 10.1080/09540121.2019.1595509
– ident: e_1_2_12_30_1
  doi: 10.7448/IAS.19.1.21106
– ident: e_1_2_12_33_1
  doi: 10.1371/journal.pmed.1003042
– ident: e_1_2_12_18_1
  doi: 10.1093/infdis/jir353
– ident: e_1_2_12_20_1
  doi: 10.1016/S2214-109X(22)00413-2
– ident: e_1_2_12_4_1
  doi: 10.1056/NEJMoa1809866
– ident: e_1_2_12_31_1
  doi: 10.15585/mmwr.mm6948a1
– ident: e_1_2_12_10_1
  doi: 10.1002/jia2.25048
– ident: e_1_2_12_24_1
– ident: e_1_2_12_29_1
  doi: 10.1111/j.0006-341X.2001.00120.x
– ident: e_1_2_12_57_1
  doi: 10.1002/jia2.26005
– ident: e_1_2_12_26_1
  doi: 10.1016/S2352-3018(19)30190-0
– ident: e_1_2_12_28_1
  doi: 10.1177/019251396017003001
– ident: e_1_2_12_15_1
  doi: 10.1093/infdis/jiab021
– ident: e_1_2_12_25_1
  doi: 10.1097/QAD.0000000000002989
– ident: e_1_2_12_8_1
– ident: e_1_2_12_14_1
  doi: 10.1093/cid/ciaa413
– ident: e_1_2_12_27_1
  doi: 10.1016/j.drugalcdep.2021.109005
– ident: e_1_2_12_6_1
– ident: e_1_2_12_7_1
  doi: 10.1056/NEJMoa1702150
– ident: e_1_2_12_45_1
  doi: 10.1371/journal.pone.0256865
– ident: e_1_2_12_51_1
  doi: 10.1016/S2352-3018(20)30359-3
– volume: 25
  issue: 3
  year: 2022
  ident: e_1_2_12_53_1
  article-title: Population trends in HIV service delivery, viral suppression, and incidence before and during the COVID‐19 era in Rakai, Uganda
  publication-title: J Int AIDS Soc
– ident: e_1_2_12_23_1
  doi: 10.1016/S0140-6736(23)00877-2
– ident: e_1_2_12_13_1
  doi: 10.1097/QAI.0000000000002508
– ident: e_1_2_12_48_1
  doi: 10.1007/s10461-022-03582-z
– ident: e_1_2_12_16_1
  doi: 10.1016/S2352-3018(16)30034-0
– ident: e_1_2_12_42_1
  doi: 10.1056/NEJMp1710608
– ident: e_1_2_12_34_1
  doi: 10.1016/S2352-3018(19)30407-2
– reference: 37398460 - medRxiv. 2023 Jun 16:2023.06.15.23291445. doi: 10.1101/2023.06.15.23291445.
SSID ssj0062849
Score 2.341707
Snippet Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are...
Population-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We...
Introduction: Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are...
In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance...
IntroductionPopulation-level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are...
Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in...
SourceID doaj
proquest
gale
pubmed
crossref
wiley
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage e26200
SubjectTerms AIDS (Disease)
AIDS research
Alcohol use
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
antiretroviral therapy
Antiviral agents
Apprenticeship
Care and treatment
Cohort analysis
Cohort Studies
Diagnosis
Disease transmission
Drug resistance
Female
HIV
HIV infection
HIV Infections - diagnosis
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV treatment
HIV viraemia
HIV-1 - genetics
Households
Housework
Human immunodeficiency virus
Humans
Male
Measurement
Migration
Patient outcomes
Population
Population studies
Population-based studies
prospective cohort
Risk taking
Self report
Sexual behavior
sub‐Saharan Africa
Treat All
Uganda - epidemiology
Variables
Viral Load
Viremia
Viremia - diagnosis
Viremia - drug therapy
Viremia - epidemiology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQnpAQ4p_AAkYgkJDKJk5sJ9wKYtVdCU4t2ps1sZ1VUUir_ogrj8BD8SQ8CTN2GrUCwYVbFI_bxDMef-PMfGbsuVIN2AyDHMiVxQDFu1HtSxhJ7bTzVeWzmr7ofvioJrPi_EJe7B31RTlhkR44DtwJcVU2yisvG0IfWSW1LbQuvbYOchuidVzzdsFU9MEKnW41kJGKk89zEK-Jej09WH4CS__vvnhvMdoHrGHFOb3BrvdQkY_jI95kV3x3i12L-2w8lg_dZj-mkVuq5S6eLb_m0DnuViHfgi8a7rYrKo_ik7NPnDJ6W94uwPH1dtnnwHahx5I2zlDl3YYThfHPb9_D7XbxFS9bSi0Kvf2XOfBY28j7pA78xSm-TxCfEgbla1S8x27bJZ93fHZJuxVvOPDlcFoYNtL6iY9B9LZ32Oz0_fTdZNSfzDCykjIpHLgGJAhlZWMhz5QUqU1BF4UvtFO2yZzLMwspEKJrfFlXIBxCUZ0VzgHkd9lRt-j8fcYlOlhItYa6cUUtRelyK1zpU4AK_8El7NlOYWYZCThMpFoWhtRqgloT9pZ0OUgQaXa4gaZkelMy_zKlhD0hSzCxAnWY-masKwqcUy0S9jJI0OTfrMBCX8OAr0I0WgeSLw4kLyOJ-J8Ejw8EcXbbw-adWZreu6wNQjQMzBGrqoQ9HZqpJ2XMdX6xJRkMrCtVyDJh96I5D6OTl3lOFcsJexXs-y8Da87PxiJcPfgfQ_yQXRWICmPa-zE72qy2_hGiuk39OEzgX98WT5Y
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZguSAhxJvAAkYgkJCym6edcEEFsequBKcW9WZNPE5VFJLQh_hz_Dg8dhq2Au2tSsZJk_E8M_MNY6-FqEHHNsiBVGgboBgMK1NAmEuUaMrSxBV90f3yVUzn2cUiXwwJt81QVrnXiU5RY6cpR35qzZINRqx9Fh_6nyFNjaKvq8MIjevsBkGXUUmXXIwBl7CqtxwhSZPT7ytITgiAPTowQg6r_1-NfMkkXXZbnd05u8NuDw4jn3gO32XXTHuP3fLZNu6biO6z3zOPMNVw9BPmNxxa5Lh2VRe8qznu1tQkxafn3zjV9Ta86QD5ZtcPlbCtW9FT-swyvt1yAjIO3cGm-xU2VFzkVpofK-C-u5EPZR32ajP7LI54Rl4o31jWm3DX81XL50vKVrznwPtxWlhI1tPensBtH7D52efZp2k4zGUIdU51FAhYQw6J0HmtIY1FnkQ6ApllJpModB0jprGGCMifq01RlZCgdURlnCECpA_ZUdu15jHjuVWvEEkJVY1ZlScFpjrBwkQApb0DBuzVnlGq9_AbygMtJ4rYqRw7A_aReDhSEGS2O9Ctl2qQQEWgp7UwwuQ1ubF2u0idSVkYqRFSbS_ygnaA8v2no-CriSwpbI5kErC3joJEf7sGDUMHg30UAtE6oHxzQLn0EOL_Izw-ILSyrQ9P77ejGnTLRv2VhIC9HE_TSqqXa023IxobVpciy4uAPfLbeHw7aZGm1K8csHduX1_xYtXF-SRxv55c_U-espuJ9fZ8OfsxO9qud-aZ9da21XMnkn8AEb1AkQ
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fi9QwEA_H-SKInP_rnRpRFIT12rRJWvFlFY-9A8WHXbm3Mk3SZY-1XfYPvvoR_FB-Ej-JM0m3d4si-FaamW6b-ZOZ7MwvjD1XqgaTYJIDqTKYoDg7qFwOA6mttq4oXFLRP7ofP6nRJDs7l-d77O22FybgQ_QbbmQZ3l-TgUO1Or4EDb2YgXhNcOqYsF-j3lpCzhfZ560fVuh4C98OKVEXlBQ9OKk4vuTdWY48av-fvvnK4nQ1gPUr0MkBu9mFjnwYZH2L7bnmNrsR9t14aCe6w36OA9bUnNtw1vyKQ2O5Xfr6C97W3G6W1C7FR6dfOFX4zvm8BctXm0VXE9t4jgVtpKEKNGtOkMa_vv_wt-ftN7ycU6mR53ZfZ8BDryPvijzwiWP8Hk8-ppiUr1ARHLJtFnzW8MmUdi_ecOCL_vQwHKT1FF-D4G7vssnJh_H70aA7qWFgJFVWWLA1SBDKyNpAmuBsxyYGnWUu01aZOrE2TQzEQBFe7fKqAGExNNVJZi1Aeo_tN23jHjAu0eFCrDVUtc0qKXKbGmFzFwMU-As2Ys-2AisXAZCjDNDLoiSxll6sEXtHsuwpCETb32iX07KzyZJgUGvllJM1BbZJIbXJtM6dNhZSgw95QppQho7U3hWUQ11QIh1rEbGXnoKcwXoJBrqeBvwUgtXaoXyxQzkNoOJ_IzzaIURrN7vDW7UsO2-zKjFkw0QdY1cVsaf9MHFSBV3j2g3RYKJdqEzmEbsf1LmfnTRPU-pgjtgrr9__mNjy7HQo_NXD_yE-ZNcFRoOh3P2I7a-XG_cIo7l19dgb7W_h1Enw
  priority: 102
  providerName: Wiley-Blackwell
Title Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjia2.26200
https://www.ncbi.nlm.nih.gov/pubmed/38332519
https://www.proquest.com/docview/2931845606
https://www.proquest.com/docview/2924996458
https://doaj.org/article/0056f6e6e5f04561957c4778e7cda3c0
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ta9RAEF5q-0UQ8d1oPVcUBeHavG8iiFyl5VpoKXIpxS9hsrs5TmJy3gvqN3-CP8pf4i9xZjcX7rCIX-5CdjZ3uzuzM7OZeYaxF3FcgvTQyYEgluigaNUvdAL9SCihdJpqr6A3uqdn8TALTy6jyy22qt_ZTuD8SteO6klls2rv25fv71Dg37YAovufJuDvEbA6uu47qJEECehp2L1NiHELTk1iZIRcEUd-B1O63ndDMRn8_r936TU1tW7KGl10dIvdbI1IPrCrfptt6foOu2FP4LhNLLrLfo0s6lTFla06P-dQK65mJhKDNyVXyxklTvHh8QWnWN-KVw0oPl9O2-jY2vSY0pEaMkO94ARu_PvHT3O7ar7iZUVBR6a3_jwBbrMeeRvugU8c4XgM-YisUz5HltDYbTnlk5pnYzrHeMOBT7s6YthImhX_BgHf3mPZ0eHo_bDf1mzoy4hiLBSoEiLwYxmVEgIPZ9uVLogw1KFQsSw9pQJPggtk65U6KVLwFRqpwguVAgjus-26qfVDxiPcesEVAopShUXkJyqQvkq0C5DiLyiHPV8tWD610By5BWH2c1rW3Cyrww5oLTsKgtM2N5rZOG-lMydA1DLWsY5KMnG9NBIyFCLRQioIJD7kKXFCbnNTu00hH4iUXGpX-A57ZSiIURczkNBmN-BQCGBrg_LlBuXYwotfRbi7QYhyLzebV2yZr8QmR-MNXXa0YmOHPeuaqSfF0tW6WRINutxpHEaJwx5Ydu5mJ0iCgHKZHfba8Pc_JjY_OR745urR_47oMbvuo01og9532fZittRP0KZbFD12zQ_P8VNcih7bGVxkHzP8Pjg8O__QM-ckPSPSfwAUgFU9
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbK9gEkhLgJFGrEJSGFJs7hBAmhLbTa7SWEdlHfwsR2VouWJOyhij_FL-DH4bGT0BWob32LkrFzzHgOZ-YbQp7HcQHC10EOBLHQAYqSbq4ScCMuuVRpqvwc_-gen8SDcXhwGp1ukF9tLQymVbY60ShqWQncI9_RZkkHI9o-x-_rHy52jcK_q20LDSsWh-rnmQ7ZFu-GHzV_XzC2vzf6MHCbrgKuiDALQIIsIAIWi6gQEPhxxDzhAQ9DFXIZi8KXMvAFeIDeSKGSPAUmtRvF_VBKgEDPe4VshoEOZXpkc3fv5NPnVvfHWtmnHQgq2_k2BfYGId-9NbNnugP8awPOGcHzjrKxdPs3yY3GRaV9K1O3yIYqb5Prdn-P2rKlO-T3yGJazai0Pe0XFEpJ5dzkedCqoHI1x7IsOhh-oZhJPKOzCiRdrOom97Y0I2rcsNOiVi4pQie75uSsOnNnmM5kRqrvU6C2npI2iSR6tpF-F0M8Qr-XLrSwKXdV02lJxxPcH3lLgdZdfzIX7bW-PcLp3iXjS-HZPdIrq1I9IDTSCh08ziEvZJhHLJGBYDJRHkCq7yAd8qxlVFZbwI_MQjuzDNmZGXY6ZBd52FEgSLc5Uc0nWbPmM4RZLWIVq6hAx9lPIy5CzhPFhYRA6Em2UQIyW_HaqZqsz1MM1D3OHPLKUKCyWc5BQFMzoV8FYbvWKF-uUU4saPn_CLfWCLU2EeuXW3HMGm22yP6uPYc87S7jSMzQK1W1QhodyKdxGCUOuW_FuPs6QRIEWCHtkNdGri_4sNnBsM_M0cOLn2SbXB2Mjo-yo-HJ4SNyjWlf0ybTb5Hecr5Sj7WvuMyfNAuUkq-XrRP-AKwXgBI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwELfGkBASQrwJDGbES0IKTZzETpAQKoyq3WDiQzv1W7jaTlVUktCHJv41xB-Hz07DKtC-7VuUnJ3Hne_h3P2OkGecFyBDE-RAxKUJULTyJzoFPxFKKJ1lOpzgH93Px7w_ig_HyXiH_NrUwmBa5UYnWkWtKol75B1jlkwwYuwz7xRNWsSXg967-oePHaTwT-umnYYTkSP989SEb8u3gwPD6-eM9T4OP_T9psOALxPMCFCgCkiAcZkUEqKQJyyQAYg41rFQXBahUlEoIQD0TAqdTjJgyrhUIoyVAojMvJfIZRElIa4xMW6DPW7UftbCobLOtxmw1wj-HmwZQNsn4F9rcMYcnnWZrc3r3SDXG2eVdp103SQ7urxFrrmdPuoKmG6T30OHbjWnynW3X1IoFVULm_FBq4Kq9QILtGh_cEIxp3hO5xUoulzXTRZuaUfUuHVnhK5cUQRR9u3JeXXqzzGxyY7U32dAXWUlbVJKzGxD8y6WeIgeMF0asdP-uqazko6muFPyhgKt205lPlpuc3sE1r1DRhfCsbtkt6xKfZ_QxKh2CISASaHiScJSFUmmUh0AZOYOyiNPN4zKawf9kTuQZ5YjO3PLTo-8Rx62FAjXbU9Ui2nerP4cAVcLrrlOCnShwywRMhYi1UIqiKSZZB8lIHe1r63Sybsiw5A9EMwjLy0Fqp3VAiQ01RPmVRDAa4vyxRbl1MGX_49wb4vQ6BW5fXkjjnmj15b531XokSftZRyJuXqlrtZIY0L6jMdJ6pF7TozbrxOlUYS10h55ZeX6nA-bHw66zB49OP9J9skVownyT4Pjo4fkKjNOp8uq3yO7q8VaPzJO42ry2K5OSr5etDr4AwrwguI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Temporal+dynamics+and+drivers+of+durable+HIV+viral+load+suppression+and+persistent+high%E2%80%90+and+low%E2%80%90level+viraemia+during+Universal+Test+and+Treat+scale%E2%80%90up+in+Uganda%3A+a+population%E2%80%90based+study&rft.jtitle=Journal+of+the+International+AIDS+Society&rft.au=Rosen%2C+Joseph+Gregory&rft.au=Ssekubugu%2C+Robert&rft.au=Chang%2C+Larry+W&rft.au=Ssempijja%2C+Victor&rft.date=2024-02-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1758-2652&rft.eissn=1758-2652&rft.volume=27&rft.issue=2&rft_id=info:doi/10.1002%2Fjia2.26200&rft.externalDocID=A791061072
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-2652&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-2652&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-2652&client=summon